---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114483"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:06:48.644100+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q3 revenue $8.1M (-17%); pauses STAR-D trial to focus on STAR-T

## Summary
- Q3 total revenue $8.1M (-17% YoY); product sales $6.5M (-27%) with negligible COVID sales.
- Product gross margin 55% (64% ex-write-off) vs 82% Q3 2021; inventory write-off of ~$0.6M from equipment failure.
- Pausing STAR-D trial to focus on STAR-T pivotal study; expects first milestone (40 patients enrolled) in Nov 2022; $4M cost savings in 2023.
- Plans to draw $15M from existing debt before year-end; ended Q3 with $24.2M cash (incl $1.7M restricted) and no debt.
- Received DoD contracts totaling ~$6.3M for HemoDefend-BGA universal plasma filter; reduced international headcount 10%.

## SEC filing metadata
- accession: 0001104659-22-114483
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465922114483/0001104659-22-114483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465922114483/tm2223902d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114483
- JSON: https://secwatch.observer/filing/0001104659-22-114483.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114483.txt

## Key facts
- Earnings Releases
  Cytosorbents Corp reported quarter ended September 30, 2022 results: revenue $8.1 million.
  - Period: quarter ended September 30, 2022
  - Revenue: $8.1 million
  - Result: reported results
  source text: and operating results for the quarter ended September 30, 2022. Third Quarter 2022 Financial Results · Total revenue, including product sales and grant income, for Q3 2022 was $8.1 million, a decrease of 17% compared to $9.8 million in Q3 2021 · Q3 2022 product sales were $6.5 million (negligible COVID-related sales) versus $8.9 million (includes $1.1 million in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465922114483/0001104659-22-114483-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.